"If you’re committed to advancing the quality and availability of medical care, you and I share a common objective. I’m looking for entrepreneurs that are changing the face of health care by combining vision and innovation with sound planning and leadership."
Nina's Latest Buzz
Nina Kjellson has been part of InterWest's life sciences team since 2002, focusing primarily on investments in biopharmaceuticals.
She is a board member of Alvine Pharmaceuticals, Cebix, Eiger Biopharmaceuticals, Labrys, Lycera, PrimeraDx, Trius Therapeutics (TSRX), Welltok and Xenon. Nina co-sponsored InterWest's investments in TESARO and Sera Prognostics where she is also a board observer. She also leads InterWest's initiative in health care IT and is a director of the Consumer Medicine Summit, a forum to address the convergence of health care and consumer innovation, and serves as a mentor to the Nike+ Accelerator and to Blueprint Health.
Prior to joining InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University.
I've always known that my career would focus on medicine and the life sciences as I am committed to advancing health care technologies and improving access to care. At InterWest, I aim to implement an investment strategy that integrates market vision and technical innovation with sound business planning and leadership. In so doing, it is my objective to partner with the entrepreneurs and scientists working to change the face of health care.